Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLN324 vs Aflibercept in Neovascular (Wet) Age-related Macular Degeneration
NCT07816315Phase 3Not yet recruiting
- Sponsor
- Ollin Biosciences
- Start
- Oct 2026
- Primary completion
- Dec 2028
01
Overview
Phase 3, randomised, double-blind trial of OLN324 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Ollin Biosciences. Primary endpoint: Best Corrected Visual Acuity at 48 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
OLN324
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07816315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816315.